RBQM's full value exceeds current financial models, with omitted factors like rework reduction and inspection readiness ...
Entrada Therapeutics reports Phase 1/2 data for ENTR-601-45 in exon 45 skipping, the most common single-exon target affecting ...
Vanda Pharmaceuticals' VQW-765 fails primary endpoint in Phase III social anxiety trial, showing no statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results